Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies-Reference-Cited by-同舟云学术

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

Published:2023-11-17 Issue:12 Volume:7 Page:e983
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Gopalakrishnan Sathej¹,Menon Rajeev²,Suleiman Ahmed A.¹,Kater Arnon P.³,Stilgenbauer Stephan⁴,Seymour John F.⁵,Chyla Brenda⁶,Lu Tong⁷,Young Kim Su⁸,Roberts Andrew W.⁵,Woyach Jennifer A.⁹,Mensing Sven¹,Salem Ahmed Hamed²¹⁰^ORCID

Affiliation:

1. Clinical Pharmacology, AbbVie, Ludwigshafen, Germany

2. Clinical Pharmacology, AbbVie, North Chicago, IL, USA

3. Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, on behalf of HOVON CLL WG, Amsterdam, The Netherlands

4. Division of CLL, Department III of Internal Medicine, Ulm University, Ulm, Germany

5. Department of Hematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, University of Melbourne, Parkville, VIC, Australia

6. Precision Medicine Oncology, AbbVie, North Chicago, IL, USA

7. Genentech Inc, South San Francisco, CA, USA

8. Oncology Development, AbbVie, North Chicago, IL, USA

9. Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

10. Clinical Pharmacy, Ain Shams University, Cairo, Egypt

Publisher